Lonza is a leading global manufacturing partner to the pharmaceutical, biotech, and nutrition industries, renowned for its high-quality services and innovative solutions.

Founded in 1897, Lonza has grown to become a key player in contract development and manufacturing organisation (CDMO) services. The company provides integrated solutions for the development, production, and scaling of therapies that address some of the world's most pressing health challenges. With headquarters in Basel, Switzerland, Lonza operates across four key segments: biologics, small molecules, cell and gene therapies, and capsules and health ingredients.

Lonza’s expertise spans from early-stage development through to commercial manufacturing. Its offerings are underpinned by state-of-the-art technologies, a robust global network, and a commitment to sustainability. The company’s mission is to enable customers to bring life-saving products to market faster while ensuring quality and compliance at every step.

Key Products and Services

• Biologics: Comprehensive services including cell line development, process optimisation, and large-scale manufacturing.
• Small Molecules: Development and production of active pharmaceutical ingredients (APIs) and intermediates.
• Cell and Gene Therapy: Tailored solutions for advanced therapy medicinal products (ATMPs), from process development to clinical supply.
• Capsules and Health Ingredients: Innovative delivery systems and nutraceutical solutions for the pharmaceutical and dietary supplement markets.

Lonza continues to be a trusted partner to the life sciences industry, offering innovative solutions to drive progress in healthcare. With a strong emphasis on collaboration, quality, and sustainability, the company is well-positioned to meet the evolving needs of its global clients.